I watched this one with great interest. especially the direct questions regarding near term catalysts. They seem to be pinning a lot of hope on these local hospitals using the drug in a last resort scenario. James was hinting that he thought that could impact the FDA regulatory process in a positive way. That's all well and good but I'm curious what the hold up is with the FDA approval on the drug's existing merits. They've done the preclinical testing, they've achieved QIDP status long ago. Is there a major snag that has been hit regarding safety or other factor? I've read and watched everything this Co has ever released and the recent vagueness concerns me.
RCE Price at posting:
21.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)